Silo pharma announces collaboration with university california san francisco to study psilocybin as an anti-inflammatory agent in parkinson's and bipolar patients

Englewood cliffs, nj, june 08, 2021 (globe newswire) -- silo pharma, inc. (otcqb: silo) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has entered into a scientific research agreement (sra) with the university of california san francisco (ucsf). this sra will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited parkinson's, bipolar disorder, and chronic back pain.
SILO Ratings Summary
SILO Quant Ranking